Finding the right dosage for any medication is essential, as everyone responds differently. This is equally true for GLP-1 medications. Our clinical team will work closely with you to determine the most suitable dose, balancing the desired effects with any side effects you may experience.
Mounjaro, for example, has three stable treatment doses: 5mg, 10mg, and 15mg. Additionally, there are intermediary doses of 2.5mg, 7.5mg, and 12.5mg, which help transition between these stable doses.
In practice, this means that treatment with Mounjaro will typically begin at 2.5mg per week for the first four weeks. If you tolerate this well and experience no significant side effects, we will generally increase the dose to 5mg from the second month. However, if you do experience side effects, we may keep you on 2.5mg for a longer period to allow your body time to adjust before increasing the dose.
Once you reach 5mg, we will usually maintain this dose for a few months unless your weight loss progress is minimal. While progress varies between individuals, a useful benchmark is a minimum weight loss of approximately 1% of your starting weight per month.
If you continue to make good progress at 5mg, we may agree that there is no need to increase the dose further. You can remain on this dose for as long as necessary. However, if progress slows, we may increase the dose to 7.5mg for a month or two before stepping up to the next stable dose of 10mg.
At this stage, we would typically maintain the 10mg dose for a few months. Together, we will keep an eye on your progress and decide whether to continue at this level or increase to the maximum dose if necessary.
Our goal is gradual and sustainable weight loss. GLP-1 treatment is not a "quick fix" but rather a long-term approach to improving your health and maintaining a healthy weight.
What happens when I reach my goal weight?
Once you achieve your target, we will work with you to determine the most appropriate dose to maintain your weight. For some, this will be the current dose, while others may step down to the next stable dose. Our clinical team will closely monitor your progress and help you find the right dosage to maintain a healthy weight and overall well-being.
Dr Matthew Noble
Take charge of how you look and feel.
Backed by science. Guided by experts.
SheMed’s medical weight loss programme combines expert care and science-backed treatment to help you feel and look your best — for life.
SheMed’s medical weight loss programme combines expert care and science-backed treatment to help you feel and look your best — for life.
The content on the SheMed blog is provided for general informational and educational purposes only. While SheMed provides professional weight loss services and strives to ensure the information shared is accurate and up to date, we make no representations or guarantees as to its accuracy, completeness, or timeliness. This content should not be taken as personal medical advice or a substitute for consultation with a qualified healthcare provider. Always speak with your doctor or licensed medical professional about your individual health or medical needs before starting any new treatment or programme. Never disregard or delay seeking professional medical advice because of something you have read on this site. SheMed is not responsible for any actions you may take based on the information provided in this blog.
We are thrilled to announce a monumental milestone for the SheMed community: we have successfully raised $50 million in Series A funding, officially valuing SheMed at $1 billion and cementing our status as a Unicorn company.
This landmark investment is more than just capital; it is a powerful validation of our mission and the extraordinary, unmet demand for truly personalised, women-focused healthcare.
Validation of Our Mission: Personalised Care
In less than a year since our founding in April 2024, SheMed has grown into the UK’s fastest-growing GLP-1 programme, empowering over 60,000 members with a sustainable path to better health. This journey has been driven by the need to replace 'one-size-fits-all' treatments with clinically precise, compassionate, and accessible care.
As our Co-Founder and CEO, Olivia Ferro, explains:
“Achieving unicorn status validates the scale of the unmet needs for world-class GLP-1 care. Having been a GLP-1 patient myself, I know how transformative the right diagnosis and treatment can be. We built SheMed to give women the personalised support I struggled to find: care that listens, understands, and empowers.”
Accelerating Our UK Expansion and Innovation
This new funding will be strategically invested to significantly expand our operations across the United Kingdom and enhance the quality of care our members receive.
The investment will be used to:
- Scale Our Teams: Grow our medical, clinical, and technology teams to ensure every member receives best-in-class support.
- Strengthen Clinical Infrastructure: Enhance our capabilities and platform to maintain clinical excellence and safety.
- Advance Research: Support new research initiatives, including the upcoming publication of the first-ever female-focused GLP-1 clinical study. These findings will provide critical insights into how these medications affect women's unique hormonal and metabolic responses, helping us refine future treatment pathways for all women.
Co-Founder and President, Chloe Ferro, emphasises the market demand:
"The demand for SheMed's services has been extraordinary. Women are seeking care that recognises their individuality, their biology, and their experiences. It's why women continue to turn to SheMed for a tailored, more supportive path to healthcare.”
The SheMed Difference: Built By Women, For Women
SheMed is redefining weight management and women’s metabolic health by integrating advanced medical oversight, data-driven insights, and continuous support through an all-in-one digital platform.
Our dedication to clinical precision is paramount. Unlike standard telehealth providers, SheMed requires a comprehensive at-home blood test for eligibility and tracking. This crucial step ensures that treatment plans are safe and tailored to your specific biology, providing you with a foundation for lasting health results.
This $50 million funding round marks the beginning of our next chapter—a chapter dedicated to scaling our impact and delivering truly world-class, personalised healthcare to every woman in the UK.
Thank you to our members and our partners for believing in the SheMed mission. We are just getting started.
When new medical studies are released, they can feel full of numbers and complex terms. At SheMed, our role is to help you understand what they really mean for you, your health, and your future.
Recently, Novo Nordisk released the results of the STEER study, one of the most significant pieces of research yet on GLP-1 medicines like Wegovy. And the findings show something powerful: Wegovy is not only about weight loss, it’s also about heart health.
The Big Picture: What the STEER Study Looked At
The STEER study explored how GLP-1 medicines affect heart health in people living with Overweight or Obesity and established cardiovascular disease (but without diabetes).
Researchers compared Wegovy (Semaglutide 2.4mg) with Tirzepatide (Mounjaro). They focused on the risk of serious heart problems, what doctors call “major adverse cardiovascular events” (MACE). These include:
- Heart attack
- Stroke
- Death from heart disease
What They Found
The results were striking:
- For people who stayed on treatment without big gaps, Wegovy reduced the risk of heart attack, stroke, or cardiovascular death by 57% more than Mounjaro.
- When looking at all treated people, even those with breaks in care Wegovy still showed a 29% reduction in these serious events overall.
In short, Wegovy is not only helping people lose weight, it is also showing clear cardiovascular protection, especially when used consistently.
Why This Matters for You
We’ve always known GLP-1 medicines are powerful tools for weight loss, but the STEER study highlights something even bigger: they can also protect your heart. For anyone living with Obesity and cardiovascular disease, this is game-changing.
It also reinforces an important truth - long-term commitment matters most. The people who saw the greatest benefits were those who stayed consistent with their medication. That’s why at SheMed, we design every part of our programme to keep you supported, motivated, and engaged for the long run.
The SheMed Difference: Seeing the Bigger Picture
Medication is only one part of your health journey. At SheMed, we combine Wegovy with wraparound care:
- Regular blood tests to track key markers like cholesterol, blood sugar, and liver health.
- Weekly check-ins and app reminders to help you stay on track.
- Education and content designed specifically for women, covering sleep, hormones, activity, and nutrition.
- Proactive Side effect care and support to keep you comfortable and supported as your body adjusts.
This holistic approach matters because weight loss is just one marker of progress. By running blood tests before starting the programme, at 6 months, and 12 months, we can show you the deeper changes happening inside your body, improvements in cholesterol, blood sugar, and overall metabolic health.
It means you’ll see the true value of GLP-1s, not just in how you look or feel, but in the measurable ways your health is improving and your risks are reducing.
Why Wegovy Through SheMed Makes Sense
At SheMed, we’ve worked hard to make Wegovy accessible and affordable. With static, transparent pricing across doses, our members know exactly what they’re paying. That means no hidden surprises and no price hikes as you move up through titration.
When you combine that cost benefit with the evidence from STEER that Wegovy offers not just weight loss but cardiovascular protection the case for choosing Wegovy through SheMed becomes even stronger.
You’re not just investing in weight management; you’re investing in heart health, future health, and a programme designed to keep you safe and supported every step of the way.
The Future of Health With SheMed
The STEER study is a reminder that the story of GLP-1s is still unfolding and it’s about so much more than weight loss. These medicines are changing how we think about obesity, cardiovascular health, and long-term wellbeing.
At SheMed, we’ll continue to keep you informed as new research emerges, but more importantly, we’ll keep showing you the bigger picture through your own results. With every blood test, every milestone, and every step forward, you’ll see how far you’ve come not just in weight, but in health.
Because at SheMed, you’re not just losing weight. You’re gaining health, protecting your future, and building the strongest version of you.
Subscribe to our Newsletter
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.